HCMV US28 regulation of host cell signaling in viral latency and hematopoiesis
HCMV US28 对病毒潜伏期和造血过程中宿主细胞信号传导的调节
基本信息
- 批准号:10216635
- 负责人:
- 金额:$ 25.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-15 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAllogenicBLT miceBindingBiosensorBone Marrow TransplantationCCL2 geneCD34 geneCREB1 geneCX3C ChemokinesCell Differentiation processCell LineageCell MaintenanceCell modelCellsCharacteristicsCuesCytomegalovirusDevelopmentDiseaseEGF Signaling PathwayEGF geneEnsureEpithelialEquilibriumEventFractalkineGene ExpressionGenetic TranscriptionGoalsGraft RejectionGrowth Factor ReceptorsHematopoiesisHematopoietic Stem Cell TransplantationHematopoietic stem cellsHerpesviridaeHumanImmediate-Early GenesImmuneIn VitroInfectionInflammationInflammatoryLigandsMediatingMediator of activation proteinMicroRNAsModelingMolecularMonomeric GTP-Binding ProteinsMorbidity - disease rateMutationMyelogenousMyelosuppressionOrgan TransplantationPTK2 genePathway interactionsPopulationProteinsRANTESReceptor SignalingRecombinant Delta ChemokineRegulationRoleSignal PathwaySignal TransductionSignaling MoleculeSmooth MuscleSolidStem cell transplantStimulusTherapeutic InterventionTranscriptional ActivationTransplant RecipientsTransplant-Related DisorderTransplantationViralViral ProteinsVirusVirus LatencyVirus Replicationbasebeta-Chemokinescell motilitychemokinechemokine receptorgene productgraft failurehumanized mousein vivoinhibitor/antagonistlatency-associated proteinmacrophagemigrationmonocytemortalitymouse modelmultiple omicsnovel therapeuticsnuclear factors of activated T-cellsperipheral bloodpreventprogramsreactivation from latencyreceptor expressionreceptor-mediated signalingresponsetargeted treatmenttranscriptome sequencing
项目摘要
PROJECT 3 SUMMARY
Human cytomegalovirus (HCMV) is a -herpesvirus infecting 44-100% of the population and remains a
significant cause of morbidity and mortality in solid organ transplant (SOT) and allogeneic hematopoietic stem
cell transplant (SCT) recipients. Infection in SCT patients is often associated with myelosuppression and graft
failure due to virus reactivation from latency, but the associated mechanisms are still largely unknown. HCMV
encodes multiple latency-associated gene products including the chemokine receptor US28, which binds CC-
chemokines as well as the CX3C-chmokine Fractalkine. US28 signals in both ligand-independent and ligand-
dependent manners, but the downstream signaling pathways and consequences are unique for each.
Importantly, herein we demonstrate that US28 is required for latency and/or reactivation in both in vitro CD34+
hematopoietic progenitor cells (HPCs) as well as in a humanized mouse model. In addition, we show that
US28 is sufficient to promote CD34+ HPC differentiation into myeloid lineage cells. Therefore, based upon our
exciting new findings, we hypothesize that US28 ligand-independent signaling during latency helps to maintain
latency and that ligand-specific signaling promotes CD34+ HPC differentiation into a reactivation/replication
competent myeloid lineage cell to ensure virus replication under appropriate conditions including inflammation.
US28 signaling may also contribute to other aspects of latency by acting as a biosensor to promote migration
towards inflammatory chemokines, and possibly by increasing immediate early gene expression during
reactivation. Defining the role of US28 in latency and reactivation, determining how US28 signaling intersects
with EGFR signaling, and understanding how US28 signaling influences other HCMV proteins (Projects 1 and
4) and miRNAs (Project 2) expressed during latency and manipulating EGFR signaling (Project 5) are the
goals of this proposal. We propose the following specific aims: 1) To determine how US28 signaling in CD34+
HPCs intersects with EGFR signaling pathways using a multi-omics approach; 2) To determine what molecular
characteristics of US28 mediate HCMV latency and reactivation using both in vitro CD34+ HPCs and in vivo
humanized BLT mouse models; 3) To determine what US28 signaling pathways promote CD34+ HPC
hematopoiesis also using both in vitro CD34+ HPC and in vivo huBLT models. Results of this study will
generate new virus latency and reactivation paradigms promoting the development of novel therapies to
prevent virus reactivation and to treat HCMV-mediated myelosuppression.
项目3摘要
人巨细胞病毒是一种疱疹病毒,感染44%-100%的人,至今仍是一种
实体器官移植和异基因造血干细胞致病和死亡的重要原因
细胞移植(SCT)接受者。SCT患者的感染通常与骨髓抑制和移植物有关。
失败是由于病毒从潜伏期重新激活,但相关机制在很大程度上仍不清楚。巨细胞病毒
编码多种潜伏期相关基因产物,包括趋化因子受体US28,它与CC-
趋化因子以及CX3C-chmokine Fractalkine。US28信号在配体非依赖性和配体非依赖性中都存在
依赖的方式,但下游信号通路和后果是独一无二的。
重要的是,我们在这里证明了在体外CD34+的潜伏期和/或重新激活都需要US28
造血祖细胞(HPC)以及人源化的小鼠模型。此外,我们还展示了
US28足以促进CD34+HPC向髓系细胞分化。因此,基于我们的
令人兴奋的新发现,我们假设在潜伏期US28不依赖配体的信号有助于维持
潜伏期和配体特异性信号促进CD34+HPC分化为重新激活/复制
有能力的髓系细胞,以确保病毒在适当的条件下复制,包括炎症。
US28信号也可能通过充当促进迁移的生物传感器而导致延迟的其他方面
对炎性趋化因子的作用,可能是通过增加早期基因的即刻表达
重新激活。定义US28在延迟和重新激活中的角色,确定US28信令如何交叉
EGFR信号,以及了解US28信号如何影响其他HCMV蛋白(项目1和
4)和在延迟和操作EGFR信号(项目5)期间表达的miRNAs(项目2)是
这项提案的目标。我们提出了以下具体目标:1)确定US28信号在CD34+中是如何
使用多组学方法将HPC与EGFR信号通路相交;2)确定
US28在体外和体内介导人巨细胞病毒潜伏和再激活的特性
人源化BLT小鼠模型;3)确定哪些US28信号通路促进CD34+HPC
也可以使用体外CD34+HPC和体内huBLT模型进行造血。这项研究的结果将
产生新的病毒潜伏期和重新激活范例,促进开发新的治疗方法
防止病毒再激活和治疗巨细胞病毒介导的骨髓抑制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL N STREBLOW其他文献
DANIEL N STREBLOW的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL N STREBLOW', 18)}}的其他基金
Project 2 - Novel Therapeutics for Emerging Alphavirus
项目 2 - 新兴甲病毒的新疗法
- 批准号:
10580024 - 财政年份:2019
- 资助金额:
$ 25.42万 - 项目类别:
Project 2 - Novel Therapeutics for Emerging Alphavirus
项目 2 - 新兴甲病毒的新疗法
- 批准号:
10380667 - 财政年份:2019
- 资助金额:
$ 25.42万 - 项目类别:
Project 2 - Novel Therapeutics for Emerging Alphavirus
项目 2 - 新兴甲病毒的新疗法
- 批准号:
10115598 - 财政年份:2019
- 资助金额:
$ 25.42万 - 项目类别:
HCMV US28 regulation of host cell signaling in viral latency and hematopoiesis
HCMV US28 对病毒潜伏期和造血过程中宿主细胞信号传导的调节
- 批准号:
9980283 - 财政年份:2017
- 资助金额:
$ 25.42万 - 项目类别:
HCMV US28 regulation of host cell signaling in viral latency and reactivation
HCMV US28 在病毒潜伏期和再激活过程中对宿主细胞信号传导的调节
- 批准号:
10629177 - 财政年份:2017
- 资助金额:
$ 25.42万 - 项目类别:
HCMV US28 regulation of host cell signaling in viral latency and reactivation
HCMV US28 在病毒潜伏期和再激活过程中对宿主细胞信号传导的调节
- 批准号:
10327950 - 财政年份:2017
- 资助金额:
$ 25.42万 - 项目类别:
Human Cytomegalovirus dysregulation of host hematopoietic progenitor cell signaling pathways to modulate latency and reactivation
人类巨细胞病毒对宿主造血祖细胞信号通路的失调调节潜伏期和重新激活
- 批准号:
10629163 - 财政年份:2017
- 资助金额:
$ 25.42万 - 项目类别:
Characterizing the Role of CMV Latency in Solid Organ Transplant Rejection
表征 CMV 潜伏期在实体器官移植排斥中的作用
- 批准号:
9220714 - 财政年份:2016
- 资助金额:
$ 25.42万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 25.42万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 25.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 25.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 25.42万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 25.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 25.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 25.42万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 25.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 25.42万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 25.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)